OncoTherapy Science, Inc. (TYO:4564)
27.00
+1.00 (3.70%)
Jul 3, 2025, 3:30 PM JST
OncoTherapy Science Revenue
In the fiscal year ending March 31, 2025, OncoTherapy Science had annual revenue of 750.00M JPY with 22.95% growth. OncoTherapy Science had revenue of 187.00M in the quarter ending March 31, 2025, with 29.86% growth.
Revenue
750.00M
Revenue Growth
+22.95%
P/S Ratio
9.92
Revenue / Employee
15.96M
Employees
54
Market Cap
7.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 750.00M | 140.00M | 22.95% |
Mar 31, 2024 | 610.00M | -524.00M | -46.21% |
Mar 31, 2023 | 1.13B | -19.00M | -1.65% |
Mar 31, 2022 | 1.15B | 821.00M | 247.29% |
Mar 31, 2021 | 332.00M | 16.00M | 5.06% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Takeda Pharmaceutical Company | 4,581.55B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 866.03B |
Terumo | 1,036.17B |
Otsuka Holdings | 2,393.18B |
Astellas Pharma | 1,912.32B |
Shionogi & | 438.27B |